Genmab increases income in Q3 and maintains upgraded full-year guidance

Genmab, which recently upgraded its 2021 financial guidance, ended the third quarter with significant progress on both the top and bottom lines compared to the same period last year.

Photo: Joost Melis / Genmab / PR

During Q3 2021, Genmab generated a revenue of DKK 2310m (USD 357m) compared to DKK 1724m (USD 266m) for the same period last year. Net incomes totaled DKK 890m (USD 173.4m) in the third quarter of 2021, compared to DKK 530m (USD 81.8m) in the same period of 2020.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Extra data boosts Lundbeck's agitation case

Pharmaceutical firm Lundbeck has presented positive new data at a US conference as it seeks approval for its candidate Rexulti as a treatment for agitation in Alzheimer’s patients.

Further reading

Related articles

Latest news

See all jobs